Tecentriq Plus Chemotherapy Approved for Small Cell Lung Cancer
The Food and Drug Administration (FDA) has approved Tecentriq, in combination with carboplatin and etoposide for the first-line treatment of patients suffering from extensive-stage small cell lung cancer. Out of total lung cancers, about 10% to 15% consist of small cell lung cancer. When this type of cancer is found, it is generally at an advanced stage and thus, patients are not left with many treatment options. However, the SCLC treatments are advancing gradually and few new drugs have been approved to treat SCLC. One type of such drugs is Tecentriq. It works by blocking PD-L1, a type of protein on cancer cells that prevent the immune system from attacking them. "Tecentriq is the first cancer immunotherapy approved for the initial treatment of extensive-stage small cell lung cancer (ES-SCLC), which is especially difficult to treat," said Sandra Horning, Roche's chief medical officer and head of Global Product Development. This FDA approval has been based on data from phase 3